公开(公告)号：US20240358667A1

公开(公告)日：2024-10-31

申请号：US18759320

申请日：2024-06-28

Applicant: Flamel Ireland Limited

Inventor： Claire Mégret ,  Hervé Guillard ,  Jean-François Dubuisson

IPC: A61K31/22 ,  A61K9/14 ,  A61K9/16 ,  A61K9/50 ,  A61K31/19

CPC classification number: A61K31/22 ,  A61K9/14 ,  A61K9/1676 ,  A61K9/5015 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/19

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

公开(公告)号：US20240358666A1

公开(公告)日：2024-10-31

申请号：US18758081

申请日：2024-06-28

Applicant: Flamel Ireland Limited

Inventor： Jordan Dubow ,  Hervé Guillard ,  Claire Mégret ,  Jean-François Dubuisson

IPC: A61K31/22 ,  A61K9/14 ,  A61K9/16 ,  A61K9/50 ,  A61K31/19

CPC classification number: A61K31/22 ,  A61K9/14 ,  A61K9/1676 ,  A61K9/5015 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/19

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

公开(公告)号：US20240226023A1

公开(公告)日：2024-07-11

申请号：US18416548

申请日：2024-01-18

Applicant: Ironshore Pharmaceuticals & Development, Inc.

Inventor： David Lickrish ,  Feng Zhang

IPC: A61K9/50 ,  A61K9/00 ,  A61K9/16 ,  A61K9/48 ,  A61K31/137 ,  A61K31/4458

CPC classification number: A61K9/5073 ,  A61K9/0053 ,  A61K9/1676 ,  A61K9/4808 ,  A61K9/4866 ,  A61K9/5015 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/137 ,  A61K31/4458

Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.

公开(公告)号：US20240180861A1

公开(公告)日：2024-06-06

申请号：US18531095

申请日：2023-12-06

Applicant: Flamel Ireland Limited

Inventor： Jordan Dubow ,  Hervé Guillard ,  Claire Mégret ,  Jean-François Dubuisson

IPC: A61K31/22 ,  A61K9/14 ,  A61K9/16 ,  A61K9/50 ,  A61K31/19

CPC classification number: A61K31/22 ,  A61K9/14 ,  A61K9/1676 ,  A61K9/5015 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/19

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

公开(公告)号：US11896722B2

公开(公告)日：2024-02-13

申请号：US17647149

申请日：2022-01-05

Applicant: Purdue Pharma L.P.

Inventor： Ricardo Alberto Vargas Rincon ,  Joseph Reiz

IPC: A61K9/50 ,  A61K9/48 ,  A61K9/14 ,  A61K47/06 ,  A61P25/00 ,  A61P25/26 ,  A61K31/4458 ,  A61K9/16

CPC classification number: A61K9/5078 ,  A61K9/14 ,  A61K9/1676 ,  A61K9/48 ,  A61K9/5026 ,  A61K9/5036 ,  A61K9/5084 ,  A61K31/4458 ,  A61K47/06 ,  A61P25/00 ,  A61P25/26

Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.

公开(公告)号：US11883496B2

公开(公告)日：2024-01-30

申请号：US16902176

申请日：2020-06-15

Applicant: ADOCIA

Inventor： You-Ping Chan ,  Alexandre Geissler ,  Romain Noel ,  Richard Charvet ,  Nicolas Laurent

IPC: A61K38/28 ,  A61K47/34 ,  A61K47/62 ,  C07K14/62 ,  A61P3/08 ,  A61K9/50 ,  A61K9/20 ,  A61K9/00 ,  C08G69/10 ,  A61K47/42

CPC classification number: A61K47/34 ,  A61K9/0019 ,  A61K9/2045 ,  A61K9/5084 ,  A61K38/28 ,  A61K47/42 ,  A61K47/62 ,  A61P3/08 ,  C07K14/62 ,  C08G69/10

Abstract: A physically stable compositions in the form of an injectable aqueous solution with a pH from 6.0 to 8.0, include a basal insulin whose isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.

公开(公告)号：US11883474B2

公开(公告)日：2024-01-30

申请号：US18049791

申请日：2022-10-26

Applicant: Theriva Biologics, Inc.

Inventor： Michael Kaleko ,  Sheila Connelly

IPC: A61K38/50 ,  A61K9/00 ,  A61K9/48 ,  A61K9/50 ,  A61K31/424 ,  A61K38/14

CPC classification number: A61K38/50 ,  A61K9/0053 ,  A61K9/4808 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/4891 ,  A61K9/5026 ,  A61K9/5084 ,  A61K31/424 ,  C12Y305/02006 ,  A61K38/14

Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption from orally administered antibiotics.

公开(公告)号：US20230381111A1

公开(公告)日：2023-11-30

申请号：US18074482

申请日：2022-12-04

Applicant: Anovotek, LLC

Inventor： Daniel Alexander ,  Don Alexander

IPC: A61K9/50 ,  A61K9/08 ,  A61K31/00 ,  A61K45/06

CPC classification number: A61K9/5084 ,  A61K9/08 ,  A61K31/658 ,  A61K45/06

Abstract: A fluid system includes first microencapsulations encapsulating an active ingredient and a fluid holding the microencapsulations in suspension. A second active ingredient is in the fluid. The microencapsulations remain intact, rupture when exposed to friction, or dissolve upon passage of a period of time or based on another trigger event. A third active ingredient may be provided. A system is provided that includes a material embedded or coated with the provided fluid. The active ingredient may be a THC-free CBD isolate. An exemplary method provides exposure to a first active ingredient and a second active ingredient. Exposure to the first active ingredient and/or the second active ingredient may alleviate symptoms of arthritis, or repel insects.

公开(公告)号：US11826335B2

公开(公告)日：2023-11-28

申请号：US18096508

申请日：2023-01-12

Applicant: Flamel Ireland Limited

Inventor： Jordan Dubow ,  Hervé Guillard ,  Claire Mégret ,  Jean-François Dubuisson

IPC: A61K31/22 ,  A61K9/16 ,  A61K9/50 ,  A61K31/19 ,  A61K9/14

CPC classification number: A61K31/22 ,  A61K9/14 ,  A61K9/1676 ,  A61K9/5015 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/19

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

公开(公告)号：US20230263810A1

公开(公告)日：2023-08-24

申请号：US17951981

申请日：2022-09-23

Applicant: Ojai Energetics PBC

Inventor： William KLEIDON

IPC: A61K31/00 ,  A61K45/06 ,  A61K9/50 ,  A61K9/00 ,  A61P31/16

CPC classification number: A61K31/658 ,  A61K45/06 ,  A61K9/5084 ,  A61K9/0053 ,  A61P31/16

Abstract: The present disclosure provides compositions, systems, and methods for treating